Integrum AB Stock Soars 41.2% on U.S. Sales Surge

YD Bio's stock price dropped 10.4% in pre-market trading on September 2, 2025, reflecting significant market sentiment shifts and strategic developments within the company.

Integrum AB, a leader in osseointegration technology, has implemented strategic reforms in the U.S. market, focusing on streamlined insurance processes and cost-cutting measures. These efforts aim to enhance profitability and shareholder value ahead of a potential acquisition. The company's U.S. sales surged by 41.2% in Q1 2025/26, contributing to 82% of total revenue. However, import tariffs reduced gross margins to 67% from 81% the prior year.

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, has made a SEK 44-per-share takeover offer, representing a 124% premium over Integrum's July 21, 2025, closing price. This offer has gained support from Grant Thornton and major shareholder Rickard Brånemark, highlighting market confidence in the synergies between the two companies. Despite a Q1 operating loss of SEK 12.4 million, Integrum's P/S ratio of 9.26 and U.S. expansion efforts suggest a path to profitability, though regional concentration and product reliance remain risks.